VivaVision's VVN461 Shows Promising Results in Phase 2 Trial for Non-Infectious Anterior Uveitis Treatment VivaVision Biotech celebrates significant success with VVN461, revealing promising efficacy and safety results in treating Non-Infectious Anterior Uveitis in their Phase 2 trial.

VivaVision's VVN461 Shows Promising Results in Phase 2 Trial for Non-Infectious Anterior Uveitis Treatment #China #VivaVision #VVN461 #Wenzhou #NIAU

VivaVision's VVN461 Shows Promising Results in Inflammation After Cataract Surgery VivaVision Biotech shares encouraging results from its Phase 2 trial of VVN461, a new treatment aimed at reducing inflammation post-cataract surgery, demonstrating significant efficacy and safety.

VivaVision's VVN461 Shows Promising Results in Inflammation After Cataract Surgery #China #VivaVision #VVN461 #cataract_surgery #Wenzhou